Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
75
NUVB Quote, Financials, Valuation and Earnings
Last price:
$8.55
Seasonality move
:
-2.71%
Day range:
$8.15 - $8.70
52-week range:
$1.54 - $8.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
108.58x
P/B ratio:
8.99x
Volume:
6.1M
Avg. volume:
10.3M
1-year change:
208.66%
Market cap:
$2.9B
Revenue:
$7.9M
EPS (TTM):
-$0.64
Analysts' Opinion
-
Consensus RatingNuvation Bio, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.25, Nuvation Bio, Inc. has an estimated upside of 19.88% from its current price of $8.55.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $8.55.
Fair Value
-
According to the consensus of 7 analysts, Nuvation Bio, Inc. has 19.88% upside to fair value with a price target of $10.25 per share.
NUVB vs. S&P 500
-
Over the past 5 trading days, Nuvation Bio, Inc. has overperformed the S&P 500 by 6.15% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Nuvation Bio, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nuvation Bio, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Nuvation Bio, Inc. reported revenues of $13.1M.
Earnings Growth
-
Nuvation Bio, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Nuvation Bio, Inc. reported earnings per share of -$0.16.
Enterprise value:
2.6B
EV / Invested capital:
4.85x
Price / LTM sales:
108.58x
EV / EBIT:
--
EV / Revenue:
96.84x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-13.07x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$13.1M
Return On Assets:
-38.11%
Net Income Margin (TTM):
-813.07%
Return On Equity:
-52.16%
Return On Invested Capital:
-43.02%
Operating Margin:
-430.14%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $2.2M | $26.7M | $727K | $13.1M | |
| Gross Profit | -$238K | -$1.2M | $13.1M | -$950K | $9.2M | |
| Operating Income | -$103.3M | -$134.4M | -$233M | -$48.1M | -$56.4M | |
| EBITDA | -$103.1M | -$133.9M | -$231.6M | -$47.9M | -$55.9M | |
| Diluted EPS | -$0.38 | -$2.17 | -$0.64 | -$0.15 | -$0.16 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $796.6M | $681.4M | $625.3M | $565M | $577.5M | |
| Total Assets | $797.8M | $686.5M | $630.9M | $571.6M | $601.6M | |
| Current Liabilities | $13.3M | $14M | $16.1M | $59M | $68.1M | |
| Total Liabilities | $28.4M | $18.6M | $19.3M | $68.9M | $275.7M | |
| Total Equity | $769.4M | $667.9M | $611.6M | $502.7M | $325.9M | |
| Total Debt | -- | $3.4M | $2.5M | $985K | $200.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$69.1M | -$99.1M | -$190M | -$31.1M | -$52.9M | |
| Cash From Investing | -$46.1M | $104.1M | $64.2M | $29.1M | -$96.6M | |
| Cash From Financing | $915K | $1.4M | $193.6M | -$1.5M | $501K | |
| Free Cash Flow | -$69.3M | -$99.3M | -$198.2M | -$31.2M | -$60.9M | |
NUVB
Sector
Market Cap
$2.9B
$28.5M
Price % of 52-Week High
98.28%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
0.96%
-1.33%
1-Year Price Total Return
208.66%
-20.32%
Beta (5-Year)
1.580
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.06
200-day SMA
Buy
Level
$3.02
Bollinger Bands (100)
Buy
Level
2.32 - 5.62
Chaikin Money Flow
Buy
Level
57.6M
20-day SMA
Buy
Level
$6.57
Relative Strength Index (RSI14)
Buy
Level
76.00
ADX Line
Buy
Level
39.17
Williams %R
Sell
Level
-3.6496
50-day SMA
Buy
Level
$5.13
MACD (12, 26)
Buy
Level
1.00
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
59.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.6894)
Buy
CA Score
(Annual)
Level (0.1669)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (12.9004)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, NUVB has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NUVB average analyst price target in the past 3 months is $10.25.
-
Where Will Nuvation Bio, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nuvation Bio, Inc. share price will rise to $10.25 per share over the next 12 months.
-
What Do Analysts Say About Nuvation Bio, Inc.?
Analysts are divided on their view about Nuvation Bio, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nuvation Bio, Inc. is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Nuvation Bio, Inc.'s Price Target?
The price target for Nuvation Bio, Inc. over the next 1-year time period is forecast to be $10.25 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NUVB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nuvation Bio, Inc. is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NUVB?
You can purchase shares of Nuvation Bio, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nuvation Bio, Inc. shares.
-
What Is The Nuvation Bio, Inc. Share Price Today?
Nuvation Bio, Inc. was last trading at $8.55 per share. This represents the most recent stock quote for Nuvation Bio, Inc.. Yesterday, Nuvation Bio, Inc. closed at $8.55 per share.
-
How To Buy Nuvation Bio, Inc. Stock Online?
In order to purchase Nuvation Bio, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NUVB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NUVB
Sector
P/E ratio
--
23.75x
PEG ratio
--
-0.01x
P/B ratio
8.99x
1.83x
Price / LTM sales
108.58x
1.60x
Growth Metrics
NUVB
Sector
Revenue growth
1704.68%
4.85%
Earnings growth
-8.23%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.15
-$0.20
Profitability
NUVB
Sector
Profitability FY 2024
$112K
$3.6M
Return on invested capital
-43.02%
-30.98%
Return on assets
-38.11%
-27.62%
Return on equity
-52.16%
-36.69%
Earnings Date
Last Earnings Date
Nov
3
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
2
Balance Sheet
NUVB
Sector
Total cash
$549M
$27.2M
Short term investments
$467M
$25.7M
Total assets
$540.6M
$79.7M
Long term debt
$200.7M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
